Fool Me Twice? - Boehringer Ingelheim, Medtronic Settle Lawsuits Alleging Deceptive Marketing

It seems like it has been really quiet on the legal settlement front in the US, but maybe corporate executives wanted to wait until things calmed down after the unofficial start of summer to let out news that some people might not think reflected well on them.  So this week it was time to announce two new legal settlements of allegations of bad behavior by corporate health were announced, as we will list in alphabetical order....Boehringer Ingelheim Settles Suits Alleging it Hid Data About Pradaxa HarmsAs per Bloomberg,Boehringer Ingelheim GmbH, the German family-owned drugmaker, agreed to pay $650 million to settle the majority of lawsuits filed over its blood thinner Pradaxa, which has been linked to more than 500 patient deaths.The major allegations were about deception, Patients and their families alleged Boehringer executives knew Pradaxa posed a deadly risk to some consumers when they brought it to the U.S. market in October 2010.In particular, as we discussed in more detail in February, 2014, Documents made public as part of patients’ Pradaxa suits showed Boehringer officials didn’t disclose to U.S. regulators a data analysis that indicated the blood-thinning drug may have caused more fatal bleeding after it was cleared for sale than in a study used to win approval.  Per the New York Times, Boehringer Ingelheim executives continued to maintainthat it stood behind the safety and efficacy of Pradaxa and continued to believe that the lawsuits lacked me...
Source: Health Care Renewal - Category: Health Management Tags: Boehringer Ingelheim deception kickbacks legal settlements manipulating clinical research marketing Medtronic Pradaxa Source Type: blogs